Skip to main navigation
Allakos Logo

Investors

Press Releases

Press Releases

January 16, 2024
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
– Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast today at 8:00 am E.T. – SAN CARLOS, Calif. , Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc.

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
Displaying 11 - 11 of 11


(Common Stock)


December 11, 2024 12:04 AM EST

Minimum 15 minutes delayed. Source: LSEG

Investor Toolkit

Print Page

Email Page

Email Alerts

RSS Feeds

  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • About
    • Overview
    • Management
    • Board of Directors
    • Scientific Advisory
  • Science
    • Overview
    • Biology
    • Siglec-8
    • Siglec-6
    • Lirentelimab (AK002)
    • AK006
    • Scientific Presentations
  • Clinical
    • Overview
    • Lirentelimab in Mast Cell and Eosinophil Driven Diseases
  • Patients
    • Allakos Commitment
    • EGID Resources
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • Financials & Filings
      • SEC Filings
      • Quarterly Reports
      • Annual Reports
    • Stock Information
      • Stock Information
    • Contact
  • Careers
    • Working at Allakos
    • Open Positions
  • Contact
  • About
    • Overview
    • Management
    • Board of Directors
    • Scientific Advisory
  • Science
    • Overview
    • Biology
    • Siglec-8
    • Siglec-6
    • Lirentelimab (AK002)
    • AK006
    • Scientific Presentations
  • Clinical
    • Overview
    • Lirentelimab in Mast Cell and Eosinophil Driven Diseases
  • Patients
    • Allakos Commitment
    • EGID Resources
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • Financials & Filings
      • SEC Filings
      • Quarterly Reports
      • Annual Reports
    • Stock Information
      • Stock Information
    • Contact
  • Careers
    • Working at Allakos
    • Open Positions
  • Contact
© 2024 Allakos Inc. All rights reserved
Allakos® and the 3-circles design are federally registered trademarks owned by Allakos Inc. Any unauthorized use is expressly prohibited.
Website Design: Hane Chow, Inc.
  • Privacy and Cookies Policy
  • Terms of Use
  • Expanded Access Policy